Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy
Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy
复制标题
DOI：
10.1080/0284186x.2017.1385841
复制
发表时间：
2018-01-01
期刊：
影响因子：
3.1
通讯作者：
Sorensen, Flemming Brandt
中科院分区：
文献类型：
--
作者：
Hansen, Torben Frostrup;Kjaer-Frifeldt, Sanne;Sorensen, Flemming Brandt
背景：新辅助化疗代表了局部晚期结肠癌的一种新的治疗方法。本研究的目的是分析肿瘤间质比（TSR）的能力，以预测疾病复发的局部晚期结肠癌患者接受新辅助chemotherapy.Material和Methods：本研究包括65例结肠癌患者接受新辅助化疗的II期试验。所有患者术前均计划接受3个周期的卡培他滨和奥沙利铂治疗。对手术切除的原发性肿瘤的苏木精和伊红染色的组织切片进行取样，并通过常规显微镜进行分析。结果：47%的原发性肿瘤手术切除后TSR低，与高TSR肿瘤相比，其T-和N-分类显著增高（P < 0.05），而与高TSR肿瘤相比，低TSR肿瘤的T-和N-分类显著增高（P < 0.05），与高TSR肿瘤相比，低TSR肿瘤的T-和N-分类显著增高（P < 0.05），与高TSR肿瘤相比，低TSR肿瘤的T-和N-分类显著增高（P < 0.05），与高TSR肿瘤相比，低TSR肿瘤的T-和N-分类显著增高（P < 0.05）。
Background: Neoadjuvant chemotherapy represents a new treatment approach to locally advanced colon cancer. The aim of this study was to analyze the ability of tumor-stroma ratio (TSR) to predict disease recurrence in patients with locally advanced colon cancer treated with neoadjuvant chemotherapy.Material and methods: This study included 65 patients with colon cancer treated with neoadjuvant chemotherapy in a phase II trial. All patients were planned for three cycles of capecitabine and oxaliplatin before surgery. Hematoxylin and eosin stained tissue sections from surgically resected primary tumors were sampled and analyzed by conventional microscopy. Patients were divided into stroma-high (>50%, i.e. TSR low) and stroma-low (50%, i.e. TSR high) for the comparison with clinical data.Results: A low TSR was found in 47% of the surgically resected primary tumors and correlated to a significantly higher T- and N-category compared, to tumors with a high TSR (p